$91.8 Million is the total value of Healthcare Value Capital, LLC's 36 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | New | ASTRAZENECA PLCcall | $10,265,000 | – | 150,000 | +100.0% | 11.19% | – |
| AMRI | Sell | ALBANY MOLECULAR RESH INC | $9,546,000 | -2.0% | 542,400 | -9.3% | 10.40% | -41.6% |
| TWM | Buy | PROSHARES TRultsht russ2000 | $7,120,000 | +79.8% | 200,000 | +100.0% | 7.76% | +7.2% |
| AZN | ASTRAZENECA PLCsponsored adr | $6,843,000 | -2.8% | 100,000 | 0.0% | 7.46% | -42.0% | |
| TEVA | TEVA PHARMACEUTICAL INDS LTDadr | $6,230,000 | +8.3% | 100,000 | 0.0% | 6.79% | -35.4% | |
| DGX | QUEST DIAGNOSTICS INC | $5,933,000 | +14.6% | 77,208 | 0.0% | 6.47% | -31.7% | |
| PFE | PFIZER INC | $5,219,000 | +11.7% | 150,000 | 0.0% | 5.69% | -33.4% | |
| LGND | LIGAND PHARMACEUTICALS INC | $3,856,000 | +44.9% | 50,000 | 0.0% | 4.20% | -13.6% | |
| QLTI | Buy | QLT INC | $3,567,000 | +154.1% | 912,200 | +160.6% | 3.89% | +51.5% |
| BIS | New | PROSHARES TRultsh nasd biot | $3,450,000 | – | 100,000 | +100.0% | 3.76% | – |
| SNY | New | SANOFIcall | $3,214,000 | – | 65,000 | +100.0% | 3.50% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDcall | $3,115,000 | – | 50,000 | +100.0% | 3.40% | – |
| B108PS | New | ACTAVIS PLC | $2,976,000 | – | 10,000 | +100.0% | 3.24% | – |
| MNKD | New | MANNKIND CORPput | $2,600,000 | – | 500,000 | +100.0% | 2.83% | – |
| CRY | Buy | CRYOLIFE INC | $2,292,000 | +1.1% | 221,000 | +10.5% | 2.50% | -39.7% |
| AMRI | ALBANY MOLECULAR RESH INCcall | $2,112,000 | +8.1% | 120,000 | 0.0% | 2.30% | -35.5% | |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $1,445,000 | -20.5% | 125,000 | -30.7% | 1.58% | -52.6% |
| ARIA | ARIAD PHARMACEUTICALS INC | $1,236,000 | +19.9% | 150,000 | 0.0% | 1.35% | -28.5% | |
| ALQA | New | ALLIQUA BIOMEDICAL INC | $1,019,000 | – | 196,000 | +100.0% | 1.11% | – |
| APRI | New | APRICUS BIOSCIENCES INC | $935,000 | – | 500,000 | +100.0% | 1.02% | – |
| BIS | New | PROSHARES TRcall | $863,000 | – | 25,000 | +100.0% | 0.94% | – |
| ARIA | ARIAD PHARMACEUTICALS INCcall | $824,000 | +19.9% | 100,000 | 0.0% | 0.90% | -28.5% | |
| FCSC | FIBROCELL SCIENCE INC | $712,000 | +74.1% | 157,769 | 0.0% | 0.78% | +3.7% | |
| ZGNX | New | ZOGENIX INC | $685,000 | – | 500,000 | +100.0% | 0.75% | – |
| CYTK | CYTOKINETICS INC | $678,000 | -15.4% | 100,000 | 0.0% | 0.74% | -49.5% | |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $654,000 | – | 25,000 | +100.0% | 0.71% | – |
| QLTI | QLT INCcall | $587,000 | -2.5% | 150,000 | 0.0% | 0.64% | -41.8% | |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $536,000 | -41.0% | 150,000 | -62.5% | 0.58% | -64.8% |
| ALIM | ALIMERA SCIENCES INC | $501,000 | -9.6% | 100,000 | 0.0% | 0.55% | -46.1% | |
| SNSS | New | SUNESIS PHARMACEUTICALS INCcall | $490,000 | – | 200,000 | +100.0% | 0.53% | – |
| SNSS | SUNESIS PHARMACEUTICALS INC | $490,000 | -3.9% | 200,000 | 0.0% | 0.53% | -42.7% | |
| AMRN | Sell | AMARIN CORP PLCcall | $468,000 | -4.5% | 200,000 | -60.0% | 0.51% | -43.1% |
| AMRN | New | AMARIN CORP PLCspons adr new | $468,000 | – | 200,000 | +100.0% | 0.51% | – |
| STML | Buy | STEMLINE THERAPEUTICS INC | $362,000 | +28.8% | 25,000 | +51.8% | 0.40% | -23.2% |
| ALIM | ALIMERA SCIENCES INCcall | $251,000 | -9.4% | 50,000 | 0.0% | 0.27% | -45.8% | |
| CLSN | Sell | CELSION CORPORATION | $214,000 | -8.2% | 80,000 | -20.0% | 0.23% | -45.3% |
| CPRX | Exit | CATALYST PHARM PARTNERS INC | $0 | – | -50,000 | -100.0% | -0.27% | – |
| POZN | Exit | POZEN INCcall | $0 | – | -50,000 | -100.0% | -0.73% | – |
| CEMP | Exit | CEMPRA INCcall | $0 | – | -40,000 | -100.0% | -1.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC | 20 | Q3 2021 | 31.3% |
| GLAXOSMITHKLINE PLC | 20 | Q3 2021 | 16.1% |
| PFIZER INC | 19 | Q3 2021 | 17.9% |
| TYME TECHNOLOGIES INC | 17 | Q3 2021 | 40.3% |
| ASTRAZENECA PLC | 14 | Q3 2021 | 12.9% |
| QUEST DIAGNOSTICS INC | 14 | Q3 2016 | 9.5% |
| CRYOLIFE INC | 13 | Q1 2017 | 6.6% |
| ANTARES PHARMA INC | 13 | Q3 2021 | 6.7% |
| AMARIN CORP PLC | 13 | Q3 2021 | 4.9% |
| CYTOKINETICS INC | 13 | Q3 2016 | 1.7% |
View Healthcare Value Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NOVELION THERAPEUTICS INC. | September 20, 2019 | 1,400,000 | 7.4% |
View Healthcare Value Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| SC 13D/A | 2019-09-20 |
View Healthcare Value Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.